The company's goal in releasing the information is to help researchers in their efforts to research and manage COVID-19.

The dataset is comprised of information from experiments Recursion conducted in collaboration with Utah State University in Logan to explore the therapeutic potential of a library of 1,672 U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved or clinical-stage compounds for managing the effect of SARS-CoV-2 in human renal cortical epithelial (HRCE) cells, according to the firm. Recursion processed the data using a deep-learning neural network in an effort to identify phenotypic profiles.

The RxRx19 dataset will give researchers access to more than 300,000 fluorescent microscopy images, Recursion said. It can be downloaded here.

Directed evolution shows promise in reducing drug discovery times
A research collaboration between scientists at the University of Leeds and AstraZeneca resulted in the development of a technique that can significantly...

Eurofins Discovery supports COVID-19 research
Eurofins Discovery has announced that it aims to accelerate COVID-19 antiviral drug discovery research.

Serimmune, Merck reach drug discovery milestone
Serimmune has used its immune mapping technology on clinical and preclinical samples provided by Merck.